China has officially launched a multicenter clinical trial for an implantable brain-computer interface (BCI) system, according to a report from the state-run Xinhua News Agency on May 19, 2026. The trial, led by researchers at Tsinghua University, involves several hospitals across the country and aims to evaluate the safety and efficacy of the device in helping patients with spinal cord injuries regain motor function.
The BCI system, named NEO, is designed to be implanted in the brain's motor cortex, where it can record neural signals and translate them into commands for external devices, such as robotic limbs or computer cursors. The trial is expected to enroll approximately 50 participants over the next two years, with initial results anticipated by late 2027.
This development follows China's broader push into neurotechnology, with significant government funding and policy support for brain science research. The country has set a goal to become a global leader in BCI technology by 2030, as outlined in its latest five-year plan.
Experts note that while similar trials have been conducted in the United States and Europe, China's multicenter approach could accelerate data collection and regulatory approval. However, challenges remain, including long-term device stability and ethical considerations around neural data privacy.
